Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P930027/S041

IMMULITE Systems PSA

Siemens Healthcare Diagnostics, Inc. · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONP930027/S041

What did the FDA decide?

The FDA record for P930027/S041 lists a 30-day notice for IMMULITE Systems PSA, with the stated purpose of moving manufacturing of a critical component within the same facility. The notice reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier. The record does not name the component, the facility, or the manufacturing steps involved, so the scope of the change cannot be described beyond the field labels.

The identifier ties this supplement to the original PMA P930027, which covers total prostate specific antigen testing for detection of prostate cancer under product code MTF in Immunology, submitted by Siemens Healthcare Diagnostics, Inc. A supplement is not a new approval of the whole system, and a manufacturing notice is not an original PMA. The reported purpose of the move does not by itself establish safety or clinical effectiveness.

FDA approval order statement

to move manufacturing of a critical component within the same facility
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Immunology
Decision date
Sep 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P930027/S041
Regulatory pathway
PMA supplement
Product code
MTF
Decision code
OK30
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.

Product code
MTF
FDA device class
3

For the original device and its historical approval scope, see PMA P930027. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P930027 · Original PMA

    IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS

  2. P930027/S041 received

    Application receipt date recorded by FDA.

  3. P930027/S041 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P930027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P930027

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA approvalSep 15, 1995FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
Glyn Rhonwy, Llanberis, Gwynedd Ll55 4el, LL554EL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records